Workflow
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns
EXASExact Sciences(EXAS) Investor Place·2024-06-13 14:12

Core Viewpoint - The stock market is performing strongly in 2024, with the S&P 500 up 12% year-to-date following a 23% increase last year, making it challenging to identify stocks that can sustain this momentum. Analysts at Jefferies Financial Group have identified three stocks expected to deliver double-digit returns over the next 12 months, with price targets ranging from 52% to 120%, averaging an 83% return. Group 1: Flutter Entertainment (FLUT) - Flutter Entertainment's stock dropped due to sports betting scandals and proposed tax hikes, but Jefferies analyst James Wheatcroft believes the reaction is exaggerated and maintains a buy rating with a one-year price target 52% above its current price of 183pershare[2][3].TheU.S.marketiscrucialforFlutter,contributing42183 per share [2][3]. - The U.S. market is crucial for Flutter, contributing 42% of total revenue, and its FanDuel platform holds a leading 52% market share [2]. - Despite the scandals, FanDuel's growth is expected to continue, and proposed tax increases in Illinois and New Jersey are not anticipated to significantly impact the company [3]. Group 2: Exact Sciences (EXAS) - Exact Sciences has faced a challenging 2024, with shares down 42%, yet Jefferies initiated coverage with a buy rating and a price target of 75 per share, indicating a 78% upside potential [4]. - The company's performance has been affected by weaker-than-expected first-quarter results, but the second half of the year is expected to improve significantly [4]. - Exact Sciences offers a stool-based test for colon cancer, which is more accessible than traditional colonoscopy, alleviating concerns about competition from potential blood tests [5]. Group 3: Pacific Biosciences (PACB) - Jefferies initiated coverage of Pacific Biosciences with a buy rating and a one-year price target of 4pershare,suggestinga1204 per share, suggesting a 120% upside from its current price of 1.82, although this is lower than the consensus target of 6.38,indicatingapotential2506.38, indicating a potential 250% growth [6][7]. - The company specializes in gene sequencing equipment, which is essential for biotechs in genomics, but has yet to achieve profitability, recording narrower losses in recent years [6][7]. - Pacific Biosciences has shown improvement in its financial performance, with losses narrowing from 1.38 per share to $1.11 per share last year, and further reducing to 29 cents per share in the first quarter of this year [7].